Latest news

Nanologica Delivers Silica to Insulin Manufacturer

17 October, 2023

Nanologica delivers silica to an insulin manufacturer in Asia against an order received last year. The delivery consists of silica for evaluation in full-scale production. The delivery is made against an order that was placed last year and Nanologica will provide the silica free of charge in return for being provided with results and insights into the final evaluation. The customer, which is one of the world’s largest insulin manufacturers, finances all other costs for

CEO Andreas Bhagwani is interviewed at Redeye after the release of the interim report Q2 2023

8 July, 2023

Intervju med vd Andreas Bhagwani gällande delårsrapporten för Q2 2023.

CEO Comment Q2 2023

7 July, 2023

ONE MILESTONE PASSED – NOW WE LOOK FORWARD During the quarter, we reached an important milestone when we were finally able to approve our product in chromatography – NLAB Saga® – and after that make the first delivery to a customer who will use it in their production of insulin. The fine-tuning of the production that we implemented at the beginning of the year were successful, and on May 3 we were able to approve

Interim Report Q2 2023 Nanologica AB (publ)

7 July, 2023

FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

Nanologica söker en Business Controller

29 June, 2023

Är du driven och motiveras av varierande arbetsuppgifter? Har du erfarenhet från producerande noterat bolag? Lockas du av en expansiv innovativ verksamhet? Då kan du vara den Business Controller som Nanologica söker! Vad får dig att trivas hos uppdragsgivaren Hos Nanologica får du jobba på ett bolag som vill förbättra för mänskligheten genom att bidra till att öka tillgängligheten till insulin och andra livsnödvändiga mediciner för patienter världen över. Bolaget är i början av en

In focus intervju med CEO Andreas Bhagwani på Redeye Growth Day 2023, 1 juni

2 June, 2023

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive